congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Edoxaban
ESC 2023 | August 25–28, 2023
Baseline demographic and clinical characteristics as predictors of adverse outcomes to improve management of patients with AF receiving edoxaban: A subanalysis of the ETNA-AF registry
Poster
Edoxaban
ESC 2023 | August 25–28, 2023
Clinical outcomes in patients receiving oral anticoagulation stratified by the presence of dose reduction criteria and older age: A subanalysis of ENVISAGE-TAVI AF
Poster
Edoxaban
ESC 2023 | August 25–28, 2023
Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year follow-up of more than 13,000 patients from the ETNA-AF-Europe study
Poster
Edoxaban
ESC 2023 | August 25–28, 2023
One-year effectiveness and safety outcomes of edoxaban treatment in Chinese patients with atrial fibrillation:
First snapshot of more than 4,800 patients from the ETNA-AF-China study
Poster
Edoxaban
ESC 2023 | August 25–28, 2023
Persistence to edoxaban treatment in patients with atrial fibrillation: Analysis from the Global ETNA-AF programme